FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1540449568> ?p ?o ?g. }

• W1540449568 endingPage "e407" @default.
• W1540449568 startingPage "e406" @default.
• W1540449568 abstract "Editor, Ranibizumab, a humanized monoclonal antibody fragment inhibits multiple biologically active isoforms of vascular endothelial growth factor (VEGF)-A, (Ferrara et al. 2006) and is approved for the treatment of neovascular age-related macular degeneration (nAMD) in many countries around the world. Benefit of ranibizumab treatment in improving best-corrected visual acuity (BCVA) has been shown mainly in the Caucasian patient population (Rosenfeld et al. 2006; Brown et al. 2009), with some evidence in the Japanese nAMD patients (Tano & Ohji 2010). EXTEND III is the first clinical trial in South Korean and Taiwanese patients with subfoveal choroidal neovascularization secondary to AMD, including all lesion subtypes (predominantly classic, minimally classic and occult with no classic component). In this 12-month, open-label, single-arm, multicentre, Phase 3 study, patients received monthly intravitreal injections of ranibizumab 0.5 mg. Here, we report the mean change in BCVA from baseline to Month 4 (primary efficacy endpoint), and safety over this time period. Of 95 enrolled patients (South Korea: 44 and Taiwan: 51) with a mean age of 71.2 years and a mean BCVA of 55.2 letters at baseline, 94 completed the Month 4 visit, whereas 1 patient discontinued owing to violation of exclusion criteria. At Month 4, there were significant improvements in the mean change ± standard error in BCVA from baseline by 9.3 ± 1.0 letters (in Taiwanese patients: 10.1 ± 1.6 and South Korean patients: 8.3 ± 1.2, both p < 0.0001, Fig. 1). The mean change in BCVA profile from baseline to Month 4 is comparable with that observed in the EXTEND I study (Tano & Ohji 2010). In EXTEND III 90.5% patients avoided BCVA loss (gain ≥0 letters). Additionally, 65.3% and 27.4% of the patients had a VA gain of ≥5 and ≥15 letters, respectively, while 98.9% of the patients lost <15 letters. Mean change in best-corrected visual acuity over time (study eye; assessed by early treatment of diabetic retinopathy study, ETDRS, like charts at an initial distance of 4 m). *p < 0.0001 vs. baseline. BCVA, best corrected visual acuity; SE, standard error; D, day. Patients received a mean ± standard deviation of 4.9 ± 0.48 injections over the 4-month treatment period. Overall, 33.7% (n = 32/95) patients experienced ocular adverse events (AEs); main ocular AEs were conjunctival haemorrhage (8.4%), retinal exudates (4.2%), and retinal haemorrhage (4.2%). Ocular AEs considered to be related to the study drug were cataract, conjunctival haemorrhage, retinal haemorrhage, reduced VA, vitreous floaters, injection-site pain and increased intraocular pressure (1.1% each). There were no Grade 3 targeted AEs reported during the 4-month period. Overall, 28.4% (n = 27/95) patients experienced nonocular AEs; the main nonocular AEs included nasopharyngitis and prostate cancer (4.2% each). Three patients reported AEs potentially related to systemic VEGF inhibition (hypertension [2.1%] and nonocular haemorrhage [1.1%]). There were no ocular serious AEs (SAEs) reported during the 4-month period. Nonocular SAEs were reported in 10 (10.5%) patients, of them only 1 (1.1%) was considered related to the study drug (blood pressure inadequately controlled). There were no deaths and discontinuations because of AEs. There were no new safety concerns observed during the 4 months of the study. The safety profiles between Taiwanese and South Korean patients were similar. In conclusion, the results of the EXTEND III study indicate that after 4 months of treatment, ranibizumab therapy is effective and well tolerated in South Korean and Taiwanese nAMD patients." @default.
• W1540449568 created "2016-06-24" @default.
• W1540449568 creator A5001866528 @default.
• W1540449568 creator A5014566687 @default.
• W1540449568 creator A5033138666 @default.
• W1540449568 creator A5037541462 @default.
• W1540449568 creator A5045508161 @default.
• W1540449568 creator A5090313885 @default.
• W1540449568 date "2012-01-26" @default.
• W1540449568 modified "2023-09-23" @default.
• W1540449568 title "Ranibizumab in South Korean and Taiwanese patients with age-related macular degeneration: primary outcome of the EXTEND III study" @default.
• W1540449568 cites W1976685144 @default.
• W1540449568 cites W2068742492 @default.
• W1540449568 cites W2091989599 @default.
• W1540449568 cites W2124415048 @default.
• W1540449568 doi "https://doi.org/10.1111/j.1755-3768.2011.02262.x" @default.
• W1540449568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22280368" @default.
• W1540449568 hasPublicationYear "2012" @default.
• W1540449568 type Work @default.
• W1540449568 sameAs 1540449568 @default.
• W1540449568 citedByCount "4" @default.
• W1540449568 countsByYear W15404495682012 @default.
• W1540449568 countsByYear W15404495682016 @default.
• W1540449568 countsByYear W15404495682019 @default.
• W1540449568 countsByYear W15404495682021 @default.
• W1540449568 crossrefType "journal-article" @default.
• W1540449568 hasAuthorship W1540449568A5001866528 @default.
• W1540449568 hasAuthorship W1540449568A5014566687 @default.
• W1540449568 hasAuthorship W1540449568A5033138666 @default.
• W1540449568 hasAuthorship W1540449568A5037541462 @default.
• W1540449568 hasAuthorship W1540449568A5045508161 @default.
• W1540449568 hasAuthorship W1540449568A5090313885 @default.
• W1540449568 hasBestOaLocation W15404495681 @default.
• W1540449568 hasConcept C118487528 @default.
• W1540449568 hasConcept C119767625 @default.
• W1540449568 hasConcept C121332964 @default.
• W1540449568 hasConcept C1276947 @default.
• W1540449568 hasConcept C141071460 @default.
• W1540449568 hasConcept C187212893 @default.
• W1540449568 hasConcept C2776403814 @default.
• W1540449568 hasConcept C2776694085 @default.
• W1540449568 hasConcept C2777802072 @default.
• W1540449568 hasConcept C2777977315 @default.
• W1540449568 hasConcept C2781100027 @default.
• W1540449568 hasConcept C71924100 @default.
• W1540449568 hasConceptScore W1540449568C118487528 @default.
• W1540449568 hasConceptScore W1540449568C119767625 @default.
• W1540449568 hasConceptScore W1540449568C121332964 @default.
• W1540449568 hasConceptScore W1540449568C1276947 @default.
• W1540449568 hasConceptScore W1540449568C141071460 @default.
• W1540449568 hasConceptScore W1540449568C187212893 @default.
• W1540449568 hasConceptScore W1540449568C2776403814 @default.
• W1540449568 hasConceptScore W1540449568C2776694085 @default.
• W1540449568 hasConceptScore W1540449568C2777802072 @default.
• W1540449568 hasConceptScore W1540449568C2777977315 @default.
• W1540449568 hasConceptScore W1540449568C2781100027 @default.
• W1540449568 hasConceptScore W1540449568C71924100 @default.
• W1540449568 hasIssue "5" @default.
• W1540449568 hasLocation W15404495681 @default.
• W1540449568 hasLocation W15404495682 @default.
• W1540449568 hasOpenAccess W1540449568 @default.
• W1540449568 hasPrimaryLocation W15404495681 @default.
• W1540449568 hasRelatedWork W2024548441 @default.
• W1540449568 hasRelatedWork W2048055194 @default.
• W1540449568 hasRelatedWork W2069070941 @default.
• W1540449568 hasRelatedWork W2320987231 @default.
• W1540449568 hasRelatedWork W2331023963 @default.
• W1540449568 hasRelatedWork W2345007432 @default.
• W1540449568 hasRelatedWork W2401680864 @default.
• W1540449568 hasRelatedWork W2414742053 @default.
• W1540449568 hasRelatedWork W2786851228 @default.
• W1540449568 hasRelatedWork W905838244 @default.
• W1540449568 hasVolume "90" @default.
• W1540449568 isParatext "false" @default.
• W1540449568 isRetracted "false" @default.
• W1540449568 magId "1540449568" @default.
• W1540449568 workType "article" @default.